Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy

Journal of Immunotherapy

Volumn 20, Issue 6, 1997, Pages 488-495

  Hernberg, Micaela ^a   Turunen, Juha Pekka ^b   Muhonen, Timo ^a   Pyrhönen, Seppo ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CD4 CD8 ratio; Lymphocyte subsets; Melanoma immunology; Melanoma prognosis; Tumor infiltrating lymphocytes (TILs)

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CD4 ANTIGEN; CD8 ANTIGEN; DACARBAZINE; LOMUSTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA; METASTASIS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0342546619     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199711000-00009     Document Type: Article

References (30)

1. Kirkwood JM. Melanoma: biology of melanoma relevant to biological therapy with interferons. In: DeVita JVT, Hellman S, Rosenberg S, eds. Biologic therapy of cancer. 2nd ed. Philadelphia: Lippincott, 1995:388-94.
2. Garbe C, Krasagakis K. Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 1993;100:239S-44S.
3. Bash JA, Teitelbaum D, Sreevalsan T, Neefe JR. Immunomodulatory activities of human leukocyte interferon in advanced cancer patients. J Biol Response Mod 1983;2:57-65.
4. Lucero MA, Magdelenat H, Fridman WH, et al. Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients. Eur J Cancer Clin Oncol 1982;18: 243-51.
5. Mitchell MS, Birnbaum MM, Davis JM. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma. J Clin Invest 1977;59:1017-26.
6. Muhonen T, Hahka-Kemppinen M, Pakkala S, Pyrhönen S. Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus inferferon treatment for metastatic melanoma. J Immunother 1994;15:67-73.
7. Bernengo MG, Lisa F, Puiatti P, Meregalli M, Berruto G, Zina G. T-cell subsets in melanoma patients evaluated by anti-T-cell monoclonal antibodies. Thymus 1983;5:223-33.
8. Bernengo MG, Lisa F, Meregalli M, De Matteis A, Zina G. The prognostic value of T-lymphocyte levels in malignant melanoma: a five-year follow-up. Cancer 1983;52:1841-8.
9. Clark WHJ, Elder DE, DuPont GI, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
10. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
11. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994;153:421-8.
12. Simony J, Rossi JF, Shishehian B, Ursule E, Radal MHP. Characterization of proliferate cells in malignant melanomas and their inflammatory infiltrates. Cancer Detect Prev 1991;15:183-7.
13. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and nonregressing malignant melanoma. J Invest Dermatol 1991;97:197-202.
14. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992;10:1919-26.
15. + ratio as a prognostic factor in patients treated with chemo-immunotherapy with metastatic melanoma. J Clin Oncol 1996;14:1690-6.
16. Landay AL, Muirhead KA. Procedural guidelines for performing immunophenotyping by flow cytometry. Clin Immunol Immunopathol 1989;52:48-60.
17. Nicholson JKA. Immunophenotyping specimens from HIV- infected persons: laboratory guidelines from the Centers for Disease Control and Prevention. Cytometry 1994;18:55-9.
18. Håkansson A, Gustafsson B, Krysander L, Håkansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996;74: 670-6.
19. Balkwill F. Interferons. Lancet 1989;1:1060-3.
20. Knop J. Immunologic effects of interferon. J Invent Dermatol 1990;95:72S-4S.
21. Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 1989;49:7086-92.
22. Pastorfide GC, Kibbi AG, de RA, et al. Image analysis of stage 1 melanoma (1.00-2.50 mm): lymphocytic infiltrates related to metastasis and survival. J Cutan Pathol 1992;19:390-7.
23. Strohal R, Marberger K, Pehamberger H, Stingl G. Immunohistological analysis of anti-melanoma host responses. Arch Dermatol Res 1994;287:28-35.
24. Schneeberger A, Koszik F, Stingl G. Immunologic host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J Invest Dermatol 1995;105:110S-6S.
25. Brocker EB, Zwadlo G, Holzmann B, Macher E, Sorg C. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer 1988;41:562-7.
26. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 1988;168:1419-41.
27. Brittenden J, Heys SD, Ross J, Eremin O. Natural killer cells and cancer. Cancer 1996;77:1226-43.
28. Markovic SN, Murasko DM. Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma. Cancer Res 1991;51:1124-8.
29. Vujanovic NL, Yasumura S, Hirabayashi H, et al. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol 1995;154:281-9.
30. + phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma. Cancer Res 1989;49:6562-5.